China Kintor's Covid drug candidate cuts hospital, death risk in trial

China's Kintor Pharmaceutical said on Wednesday its potential Covid-19 treatment proxalutamide effectively reduced the risk of hospitalisation and death in a clinical trial involving outpatients with mild to moderate symptoms.

The results came from a multi-national clinical trial with over 700 subjects across the world, mostly from the United States, recruited during April-December, 2021, who were given either proxalutamide or a placebo, the company said in a filing...